|
- Brand：Knowlux
- Model：Bottle/Aluminum foil bag/Drum/Customized to your needs
- Purity：99%
- Cas：782500-75-8
- Createtime： 2026-11-11
- Updatetime： 2026-11-03
| useage | medical intermediate，Pharmaceutical Intermediates |
| deliveryInfo | |
| appearance | White to off-white lyophilized powder (fragment); colorless to light yellow liquid |
| aliasen | |
| supplyCapacity | 10MT/Month |
| harbor | Hong Kong, Shanghai, Shenzhen |
| minorder | 1G |
| Molecular Formula: | C148H223N39O46 |
| Sample Available | Yes |
Albiglutide | CAS 782500-75-8 | GLP-1 Receptor Agonist Fusion Protein (Research Use Only) | Knowlux
Product Description
Albiglutide, CAS 782500-75-8, is a synthetic GLP-1 receptor agonist fusion protein supplied by Knowlux for laboratory research use. It is a recombinant fusion protein consisting of two tandem copies of a modified GLP-1(7-36) analogue genetically fused to human serum albumin, a design that confers resistance to DPP-IV degradation and extends the circulating half-life to approximately 6-7 days, supporting once-weekly administration. The product is supplied as a research-grade fragment or full fusion protein depending on lot specification; the GLP-1 fragment molecular formula is C148H223N39O46 with a fragment molecular weight of 3284.59 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.
Product Parameters
| Item | Specification |
|---|---|
| Product Name | Albiglutide |
| Synonyms | GSK 716155; Albugon; Naliglutide |
| CAS No. | 782500-75-8 |
| Molecular Formula | C148H223N39O46 (GLP-1 fragment) |
| Molecular Weight | 3284.59 g/mol (fragment); ~73 kDa (full fusion protein) |
| Sequence Length | GLP-1 fragment: 30 amino acids (modified GLP-1(7-36), Ala8 to Gly) |
| Key Structural Features | Tandem GLP-1 analogue fused to human serum albumin; DPP-IV resistant; extended half-life |
| Appearance | White to off-white lyophilized powder (fragment); colorless to light yellow liquid (full protein) |
| Purity | >=98.0% (HPLC); >=99.0% available on request |
| Identity | Confirmed by LC-MS and peptide mapping |
| Grade | Research grade |
| Counter-ion | Acetate (lot-specific, declared on COA) |
| Moisture | <=8.0% (Karl Fischer) |
| Storage | -20 C (fragment) or -80 C (full protein), protected from light and moisture |
| HS Code | 2937.19.00 |
| Packaging | 1 mg / 5 mg / 10 mg / 50 mg / 100 mg vial; bulk on request |
| MOQ | 10 mg (research grade); 100 mg (bulk) |
| Supply Ability | Milligram to gram scale |
| Application | Laboratory research use only |
| Origin | China |
Product Details
1. Overview
Albiglutide is a long-acting GLP-1 receptor agonist developed by GlaxoSmithKline and approved by the FDA in April 2014 under the brand names Eperzan and Tanzeum for glycaemic control in type 2 diabetes. It is structurally distinct from other GLP-1 agonists: rather than a lipidated peptide, it is a fusion protein comprising two copies of a modified GLP-1(7-36) sequence (Ala8 replaced by Gly) linked in tandem to human serum albumin. This albumin fusion strategy protects the GLP-1 moiety from DPP-IV cleavage and reduces renal clearance, yielding a half-life of 6-7 days. Albiglutide was withdrawn from the market in 2018 for commercial reasons, not safety concerns. Knowlux supplies albiglutide as a research-grade material for laboratory and analytical use; this supply is not intended for human administration and does not constitute a finished drug product.
2. Mechanism of Action
Albiglutide binds and activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release during hyperglycaemia, and slowing gastric emptying. The albumin fusion component does not engage the GLP-1 receptor directly; it serves as a carrier that prolongs the residence time of the GLP-1 moiety in circulation. Because the GLP-1 sequences are tandem-linked, each albumin molecule carries two receptor-binding domains, which may contribute to potency. Clinical studies in type 2 diabetes demonstrated HbA1c reductions comparable to other weekly GLP-1 agonists, with a gastrointestinal tolerability profile similar to the class.
3. Quality Control
| Test Item | Method |
|---|---|
| Purity | RP-HPLC or SEC-HPLC |
| Identity & molecular mass | LC-MS (deconvoluted) |
| Primary structure | Peptide mapping / amino acid analysis |
| Counter-ion content | Ion chromatography (acetate) |
| Moisture | Karl Fischer |
| Appearance | Visual |
| Related substances | RP-HPLC |
| Microbial limits | Membrane filtration (on request) |
Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.
4. Applications
-
Reference standard and impurity studies for GLP-1 receptor agonist analytical methods
-
GLP-1R binding and functional assay development
-
Formulation development for albumin-fusion long-acting injectables
-
Metabolic disease model research, including glucose homeostasis and appetite regulation studies
-
LC-MS, immunoassay and bioassay calibrators
5. Packaging, Storage & Shipping
Lyophilized powder or liquid: amber glass vial under nitrogen headspace (powder) or sealed vial (liquid). Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C or -80 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.
6. Documentation Support
Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.
About Knowlux
Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.
Compliance Statement
This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. Albiglutide was approved as a prescription medicine (Eperzan, Tanzeum) and subsequently withdrawn from the market for commercial reasons; that regulatory history is separate from this research-grade supply and does not extend to the product as sold by Knowlux. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.
